back-end weight drive us lower ep estim
invest summari lower ep estim
decreas estim base comment compani made
confer affect invest thesi thu
maintain neutral rate pt
 accord revenu ep level
level full
year ep full year ep
up-front invest new launch provid return note
ep guidanc rang equat
ep assum ep fall
 expect ep percentag total ep rel
ep full year ep thu ep
full year ep
factset consensu ep full year
ep repres full year ep therefor think consensu ep
still come lower base comment regard
annual ep progress
 valuat use blend dcf ev/ebitda analysi arriv
pt
disclosur section may found page
use blend dcf ev/ebitda analysi arriv pt
sever potenti upsid downsid risk neutral invest thesi
risk downsid includ follow gener drug price continu declin
could come increas competit key product also custom
consolid given buy consortium power negoti better price
consortium could continu caus price fall although integr meda
progress integr fall behind rel expect could pressur
stock harder follow progress meda divis
gener lot public data avail report
quarter lack meaning gener launch could make hard
off-set sale declin matur product gener industri product shorter
life cycl brand drug gener part commod busi
risk upsid includ follow could receiv approv launch
advair and/or restasi year one combin product could provid
upsid potenti consensu expect would limited-opportun larg gener
opportun integr meda could progress faster expect higher amount
synergi captur faster synergi captur could drive upsid number mylan
brand drug biosimilar busi may move forward new product
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
global pharmaceut compani develop licens manufactur market distribut gener brand name over-
the-count over-the-counter product varieti dosag form therapeut categori product portfolio includ approxim
product compani market countri territori
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker inc
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
